Japan Viscosupplementation Market Size & Outlook
Japan viscosupplementation market, 2018-2030 (US$M)
Related Markets
Japan viscosupplementation market highlights
- The Japan viscosupplementation market generated a revenue of USD 1,353.9 million in 2023 and is expected to reach USD 2,477.3 million by 2030.
- The Japan market is expected to grow at a CAGR of 9% from 2024 to 2030.
- In terms of segment, single injection was the largest revenue generating product in 2023.
- Single Injection is the most lucrative product segment registering the fastest growth during the forecast period.
Viscosupplementation market data book summary
| Market revenue in 2023 | USD 1,353.9 million |
| Market revenue in 2030 | USD 2,477.3 million |
| Growth rate | 9% (CAGR from 2023 to 2030) |
| Largest segment | Single injection |
| Fastest growing segment | Single Injection |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Single Injection, Three Injection, Five Injection |
| Key market players worldwide | DePuy Synthes, Sanofi SA, Smith & Nephew PLC, Anika Therapeutics Inc, Zimmer Biomet Holdings Inc, Ferring, Lifecore Biomedical Inc, LG Chem, Roche Holding AG |
Other key industry trends
- In terms of revenue, Japan accounted for 28.1% of the global viscosupplementation market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan viscosupplementation market is projected to lead the regional market in terms of revenue in 2030.
- Australia is the fastest growing regional market in Asia Pacific and is projected to reach USD 115.5 million by 2030.
Single injection was the largest segment with a revenue share of 42.95% in 2023. Horizon Databook has segmented the Japan viscosupplementation market based on single injection, three injection, five injection covering the revenue growth of each sub-segment from 2018 to 2030.
According to International Osteoporosis Foundation, in 2013, around 10% of the Japan’s population aged over 40 were diagnosed with osteoporosis, with 3 million cases in men and 9.8 million in women. The Japanese have high awareness about osteoporosis and in alignment with which a separate fracture registry has been established, where hip fracture data is derived every 5 years.
The Ministry of Health mandates osteoporosis screening for population along with established programs and exercises. Major industry players, such as Seikagaku Corporation, are located in the country and contribute to address the rising demand for hyaluronic acid injections.
In November 2016, the company signed an agreement with Zimmer Biomet to capture a share of the growing market in the U.S. The company manufacturers VISCO-3, which was approved by FDA in December 2015. The deal also included distribution of the company’s single-injection Gel-One and SUPARTZ-FX five-injection products.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Viscosupplementation Market Scope
Viscosupplementation Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan viscosupplementation market size, by product, 2018-2030 (US$M)
Japan Viscosupplementation Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
